Wczytywanie kursów wyceny...
Prognoza
Średnia cena docelowa analityków wynosi 5,47 € (+3117,65%). Mediana wynosi 5,47 € (+3117,65%).
| Kupuj |
4 |
| Trzymaj |
1 |
| Sprzedaj |
0 |
Dyskusje w społeczności
Nie ma jeszcze dyskusji o tym aktywie.
Rozpocznij dyskusjęWiadomości Przejdź do aktualności
Arcadia Biosciences secures $4 million through private placement
Arcadia Biosciences raised approximately $4 million in gross proceeds through a private placement, selling 3,883,496 common shares or prepaid warrants at $1.03 per share. The offering also included Series A-1 and A-2 investment options with an exercise price of $0.91; A-1 will be exercisable after shareholder approval, A-2 is immediately exercisable. H.C. Wainwright & Co. acted as sole placement agent; net proceeds are intended for working capital and general corporate purposes. The transaction is notable given a current market capitalization of $2.08 million; the company reports a current ratio of 3.79 and plans to file registration statements for resale. » Więcej na de.investing.com
Arcadia Biosciences secures $4 million through private placement
Arcadia Biosciences sold 3,883,496 common shares or prepaid warrants at a price of $1.03 each, generating gross proceeds of approximately $4 million. The transaction includes A‑1 and A‑2 warrants with an exercise price of $0.91; A‑1 warrants are valid for five years following shareholder approval, A‑2 warrants are immediately exercisable and expire 24 months after the registration statement becomes effective. H.C. Wainwright & Co. is acting as exclusive placement agent; the proceeds are intended for working capital and general corporate purposes, and the closing is expected subject to customary conditions. » Więcej na de.investing.com
Arcadia Biosciences dismisses Deloitte and appoints Ramirez Jimenez International as new auditor
Arcadia Biosciences dismissed Deloitte & Touche as its independent auditor effective March 30 and appointed Ramirez Jimenez International CPAs (RJI) to audit the quarter ended March 31, 2026 and the fiscal year ended December 31, 2026. Deloitte’s reports for 2024 and 2025 contained no adverse opinions but included an explanatory paragraph regarding going concern; the company disclosed material weaknesses in internal control over financial reporting for 2025, notably a lack of segregation of duties and deficient IT controls due to reduced staffing. Deloitte was authorized to provide RJI with information on the matters; Arcadia reports no disagreements with Deloitte. » Więcej na de.investing.com
Arcadia Biosciences stock rises after termination of Roosevelt deal
Arcadia Biosciences stock rose about 9% in pre-market trading after Roosevelt Resources terminated the securities exchange agreement dated December 4, 2024, as of December 24, 2025, in accordance with the contract. CEO T.J. Schaefer said the company will resume the review process for strategic alternatives and pointed to operational streamlining, cost reductions and growth of the coconut water brand Zola. The company still holds roughly 2.7 million common shares of Above Food Ingredients and expects additional consideration related to the sale of GoodWheat, which, together with the NASDAQ listing, should favor strategic transactions. » Więcej na de.investing.com
Arcadia Biosciences schedules annual general meeting for December 19, 2025
Arcadia Biosciences sets its 2025 annual general meeting for December 19 and says it will publish the time, location and agenda in the definitive proxy statement filed with the SEC. Shareholders must submit proposals or director nominations in writing by close of business on November 3, 2025. The company is keeping the annual meeting separate from a possible special meeting related to a Securities Exchange Agreement with Roosevelt Resources. In addition, CFO Mark Kawakami resigned effective September 12; Thomas J. Schaefer was appointed interim CFO and will take on the role in addition to his duties as CEO with no change to his compensation. Analysts see significant upside, with a $12 price target versus the current price of $4.14. » Więcej na de.investing.com
Dane finansowe spółki
| (EUR) | wrzesień 2026 | YoY |
|---|---|---|
| Przychody | 1,43 mln | 28,83% |
| Zysk brutto | 758,37 tys. | 112,91% |
| Zysk netto | 1,55 mln | 112,41% |
| EBITDA | 1,55 mln | 111,92% |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 281,57 tys. € |
Liczba akcji | 1,55 mln |
Maksimum/minimum z 52 tygodni | 3,53 € - 0,10 € |
| Dywidendy | Nie |
Beta | 0,59 |
C/Z (PE Ratio) | -0,02 |
PEG (PEG Ratio) | 0,00 |
C/WK (PB Ratio) | 0,50 |
C/S (PS Ratio) | 0,06 |
Profil spółki
Arcadia Biosciences, Inc. produkuje i wprowadza na rynek w Stanach Zjednoczonych produkty roślinne dla zdrowia i dobrego samopoczucia. Spółka zajmuje się opracowywaniem ulepszeń upraw, przede wszystkim pszenicy, aby poprawić ekonomikę gospodarstw rolnych dzięki lepszym wynikom roślin na polu, a także ich wartości jako składników żywności, produktów dla zdrowia i dobrego samopoczucia oraz ich przydatności do zastosowań przemysłowych. Spółka została założona w 2002 roku i ma siedzibę w Davis w Kalifornii.
| Nazwa | Arcadia Biosciences |
| CEO | Thomas J. Schaefer |
| Siedziba | Davis,
tx Stany Zjednoczone |
| Strona internetowa | |
| Sektor | Dobra podstawowe |
| Branża | Żywność |
| Debiut giełdowy | 15.05.2015 |
| Pracownicy | 8 |
Symbole giełdowe
| Giełda | Symbol |
|---|---|
NASDAQ | RKDA |
Frankfurt | 17DN.F |
München | 17DN.MU |